Global News

Genmab to Buy Cancer-Treatment Developer Merus For $8 Billion in Cash

Genmab said it would pay a cash premium of around 41% on Merus’s closing price on Friday for a deal giving it access to late-stage breakthrough petosemtamab.

Source: https://www.wsj.com/business/deals/genmab-to-buy-cancer-treatment-developer-merus-for-8-bln-in-cash-a7a3471a?mod=rss_Technology

#genmabbuy #cashgenmab #buycancer #cashpremium #genmab